Dr. Mario E. Lacouture Named New Chief of Dermatology at NYU Langone Hospital--Long Island
Dr. Lacouture created the first clinical and research program in oncodermatology, establishing a distinct subspecialty within dermatology and oncology.
Mario E. Lacouture, MD, has been named the new Chief of the Dermatology Division, Department of Medicine of NYU Langone Hospital--Long Island.
Dr. Lacouture will receive an academic appointment as Professor of Medicine at NYU Grossman School of Medicine, and will serve as the Medical Director of the Symptom Management Program at the Perlmutter Cancer Center on Long Island.
"The opportunity to lead NYU Langone Dermatology on Long Island aligns with my commitment to high-quality, accessible care and my fondness for the people of the Island," says Dr. Lacouture in a news release. "In addition, at the Perlmutter Cancer Center, I will build on our experience improving cancer patients' quality of life by preventing and treating skin issues during treatment, so that now more people can access our compassionate, specialized care for side effects, with a focus on the whole patient."
Before joining NYU Langone Health, Dr. Lacouture was an Attending Physician and Program Director of Oncodermatology and Research in the Dermatology Service at Memorial Sloan Kettering Cancer Center (MSKCC) in Manhattan. He was also a Professor in the Department of Dermatology at Weill Cornell Medicine in New York.
After receiving his MD degree from Javeriana University in his native country of Colombia, Dr. Lacouture completed a postdoctoral research fellowship in Immunology at Brigham and Women's Hospital in Boston. He then trained as an intern in General Surgery at Cleveland Clinic, followed by a residency in Dermatology at the University of Chicago. At Northwestern University in Chicago, Dr. Lacouture created the first clinical and research program in oncodermatology, establishing a distinct subspecialty within dermatology and oncology, dedicated to the science and care of skin, hair, and nail conditions in cancer patients and survivors. This oncodermatology model has been adopted by nearly 70% of National Comprehensive Cancer Centers.
Dr. Lacouture is a past member of the Board of Directors and Chair of the Oncodermatology Study Group for the Multinational Association of Supportive Care in Cancer and is currently on the Guidelines Committee of the American Society of Clinical Oncology. In 2021, Dr. Lacouture founded the Oncodermatology Society and now serves as its inaugural president.